Milestone Scientific (MLSS) Registration filing summary

Company overview and business model

• Patents, designs, develops, and commercializes computer-controlled injection technologies for medical and dental use, focusing on precise, efficient, and virtually painless drug delivery.

• Core technology is the DPS Dynamic Pressure Sensing platform, used in dental and medical applications, including the CompuFlo Epidural System and The Wand for dental anesthesia.

• Holds approximately 305 issued U.S. and foreign patents, with products sold in the U.S., Canada, and over 40 other countries.

• Recently received a technology-specific CPT code, expanding reimbursement potential for its CompuFlo Epidural System in pain management.

• Transitioning from R&D to a commercially focused medical device company, aiming to expand global footprint and platform applications.

Financial performance and metrics

• Net cash used in operating activities was approximately $2.9 million for each of the years ended December 31, 2025, and 2024.

• As of December 31, 2025, reported stockholders' equity was approximately $2.8 million, with losses in each of the five prior fiscal years.

• Following the private placement, stockholders' equity increased to $4.1 million.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; may receive up to $2,687,500 in gross proceeds if all warrants are exercised.

• Net proceeds from warrant exercises, if any, will be used for general working capital and payment of past due accounts payable.